

Alexander Muir Walker

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2269130/alexander-muir-walker-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

1,698
citations

21
h-index

41
g-index

58
ext. papers

1,880
ext. citations

5.1
avg, IF

4.34
L-index

#	Paper	IF	Citations
55	Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. <i>Arthritis and Rheumatism</i> , 2000 , 43, 405-13		328
54	Aprotinin during coronary-artery bypass grafting and risk of death. <i>New England Journal of Medicine</i> , 2008 , 358, 771-83	59.2	278
53	The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1994 , 37, 814-20		111
52	Coronary heart disease outcomes in patients receiving antidiabetic agents. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 711-25	2.6	90
51	Efficacy of a two-component acellular pertussis vaccine in infants. <i>Pediatric Infectious Disease Journal</i> , 1997 , 16, 1038-44	3.4	87
50	Treatment of intrathyroidal papillary carcinoma of the thyroid. <i>Cancer</i> , 1987 , 60, 2587-95	6.4	67
49	Temporal trends and drug exposures in pulmonary hypertension: an American experience. <i>American Heart Journal</i> , 2006 , 152, 521-6	4.9	65
48	Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. Women. <i>Cancer</i> , 1998 , 83, 2003-2007	6.4	58
47	Asthma drug use and the development of Churg-Strauss syndrome (CSS). <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 620-6	2.6	49
46	Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 641-52	2.6	35
45	Temporal and regional variation in hysterectomy rates in the United States, 1970--1975. <i>American Journal of Epidemiology</i> , 1979 , 110, 41-6	3.8	33
44	Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example. <i>American Journal of Epidemiology</i> , 1998 , 147, 407-13	3.8	32
43	Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, 760-8	2.6	29
42	Pattern recognition in health insurance claims databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2001 , 10, 393-7	2.6	29
41	Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the NursesXHealth Study. <i>Circulation</i> , 1998 , 97, 1540-8	16.7	29
40	Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. <i>Epidemiology</i> , 2012 , 23, 238-46	3.1	27
39	Health care resource utilization in patients with active epilepsy. <i>Epilepsia</i> , 2010 , 51, 874-82	6.4	26

38	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , 2016 , 86, 62-70	5.3	25
37	Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 47-56	2.6	24
36	Use of insurance claims in epidemiologic research: Identification of peptic ulcers, gi bleeding, pancreatitis, hepatitis and renal disease. <i>Pharmacoepidemiology and Drug Safety</i> , 1995 , 4, 239-248	2.6	24
35	Active influenza vaccine safety surveillance: potential within a healthcare claims environment. <i>Medical Care</i> , 2009 , 47, 1251-7	3.1	22
34	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 973-81	2.6	17
33	Matching on provider is risky. <i>Journal of Clinical Epidemiology</i> , 2013 , 66, S65-8	5.7	16
32	Signal detection for vaccine side effects that have not been specified in advance. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 311-7	2.6	14
31	Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, 982-8	2.6	14
30	Orthogonal predictions: follow-up questions for suggestive data. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 529-32	2.6	13
29	Misclassification of covariates. <i>Statistics in Medicine</i> , 1991 , 10, 1181-96	2.3	13
28	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2938-44	5.1	12
27	Uninformed criticism of automated record linkage. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 46, 478-9	6.1	12
26	Conjugated estrogens and fibrocystic breast disease. <i>American Journal of Epidemiology</i> , 1986 , 124, 746-51	3.8	11
25	An event-based approach for comparing the performance of methods for prospective medical product monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 631-9	2.6	10
24	Identification of esophageal cancer in the General Practice Research Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 1159-67	2.6	10
23	Age at first birth and breast atypia. <i>International Journal of Cancer</i> , 1984 , 33, 309-12	7.5	10
22	Possible Opioid Shopping and its Correlates. <i>Clinical Journal of Pain</i> , 2017 , 33, 976-982	3.5	9
21	Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 348-56	2.6	8

20	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 707-712	2.6	7
19	A comparison of wax matrix and microencapsulated potassium chloride in relation to upper gastrointestinal illness requiring hospitalization. <i>Pharmacotherapy</i> , 1989 , 9, 204-6	5.8	7
18	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 567-569	2.6	6
17	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 221-228	5.1	5
16	Tacit knowledge. <i>European Journal of Epidemiology</i> , 2017 , 32, 261-267	12.1	4
15	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 1223-5	2.6	4
14	Studies of diabetes, thiazolidinediones, and coronary heart disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 1313-4; author reply 1314-6	2.6	4
13	Precautions for proactive surveillance. <i>Pharmacoepidemiology and Drug Safety</i> , 2002 , 11, 17-20	2.6	4
12	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , 2018 , 32, 31-37	2.3	4
11	Conditional power as an aid in making interim decisions in observational studies. <i>European Journal of Epidemiology</i> , 2018 , 33, 777-784	12.1	4
10	The Pharmacoepidemiology of Psychiatric Medications 181-194		2
9	Discontinuations of antihyperlipidemic drug therapy: assessment by means of automated databases. <i>Pharmacoepidemiology and Drug Safety</i> , 1996 , 5, 113-20	2.6	2
8	Common language. <i>Pharmacoepidemiology and Drug Safety</i> , 1996 , 5, 415-8	2.6	2
7	Information on doctor and pharmacy shopping for opioids adds little to the identification of presumptive opioid abuse disorders in health insurance claims data. <i>Substance Abuse and Rehabilitation</i> , 2019 , 10, 47-55	5.5	1
6	Characterizing vaccine-associated risks using cubic smoothing splines. <i>American Journal of Epidemiology</i> , 2012 , 176, 949-57	3.8	1
5	Market surveillance--the complement to pharmacovigilance. <i>Pharmacoepidemiology and Drug Safety</i> , 1997 , 6, 370-2	2.6	1
4	Conditional power for assessing population interventions. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1027-1035	2.1	1
3	Removal of ineligible outcome cases reduces confounding. <i>Clinical Epidemiology</i> , 2018 , 10, 575-579	5.9	1

- 2 Complementary hypotheses in safety surveillance. *Sequential Analysis*, **2020**, 39, 417-430 0.7
- 1 Antibiotic prescribing patterns among patients admitted to an academic teaching hospital for COVID-19 during the first wave of the pandemic in Toronto: A retrospective, controlled study. *Jammi*, **2022**, 7, 14-22 1.4